矮小症生长激素受体基因外显子3多态性与重组人生长激素疗效相关性的Meta分析  

Meta-analysis on the association of growth hormone receptor(GHR) exon 3 polymorphism and the effect of recombinant human growth hormone(rhGH) therapy in short stature

作　　者：李鑫[1] 班博[2] 乔建敏 张艳红[2] 陈汉文[3] 王盼盼[3] LI Xin BAN Bo QIAO Jian-min ZHANG Yan-hong CHEN Han-wen WANG Pan-pan(School of Medicine, Shandong University, Jinan 250012 The Affiliated Hospital of Jining Medical College, Jining 272013, China Jining Medical College, Jining 272013, China)

机构地区：[1]山东大学医学院,山东济南250012 [2]济宁医学院附属医院,山东济宁272000 [3]济宁医学院,山东济宁272000

出　　处：《中国优生与遗传杂志》2017年第1期14-19,共6页Chinese Journal of Birth Health & Heredity

摘　　要：目的系统评价矮小症患儿生长激素受体外显子3多态性与重组人生长激素疗效的相关性。方法计算机检索Pubmed、EMbase、The CNKI、CBM、The Cochrane Library等中英文数据库,搜集有关应用重组人生长激素治疗生长激素缺乏症、特发性矮小症、Turner综合征、小儿胎龄儿的相关文献。根据Cochrane系统评价方法,进行文献资料收集、质量评价、数据提取,最后采用Revman 5.3软件以及stata12.0软件进行Meta分析。结果最终纳入17篇文献,Meta分析结果显示:rhGH治疗1年后,d3-GHR基因型身高生长速度明显高于GHRf1型,(MD=-0.75,95%CI(-0.96,-0.55),P<0.00001);而d3-GHR基因型身高标准差积分也同样高于GHRf1基因型(MD=-0.1 0SDS,95%CI(-0.18,~0.01),P=0.04)。结论在短期治疗中,d3-GHR基因型与rhGH助长效应具有一定相关性。Objective： To evaluate the effectiveness of recombinant human growth hormone （rhGH） for short stature with the growth hormone receptor （GHR） exon 3 polymorphism. Methods： The randomized controlled trials （RCTs） about in treating GHD, ISS, TS, SGA searched in Pubmed, EMbase, The CNKI, CBM, the Cochrane Library and so on.According to the Cochrane Handbook, we screened literature, assessed methodological quality, extrated date and conducted meta-analysis using Revman 5.3 software and statal2.0 software. Results： A total of 17 RCTs were including, the result of meta-analysis showed that, compared with GHRfl gene type, after 1-year treatment with rhGH, the d3-GHR gene type resulted in a significant increase in growth velocity （MD=-0.75, 95%CI （-0.96, -0.55） , P〈0.00001） , height standard deviation score （SDS） （MD=- 0.10SDS, 95%CI （-0.18, -0.01） , P=0.04） . Conclution.. In short-term treatment with rhGH, d3-GHR gene type has certain relevance about its effect of encouraged height.

关 键 词：重组人生长激素 GHR基因外显子3多态性 系统评价 META分析 

分 类 号：R725.8[医药卫生—儿科]